[MAYBANK] YoY TTM Result on 30-Jun-2022 [#2]

Announcement Date
25-Aug-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
30-Jun-2022 [#2]
Profit Trend
QoQ- -1.36%
YoY- -2.56%
View:
Show?
TTM Result
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Revenue 68,664,529 58,848,481 45,511,556 49,555,536 51,828,282 50,325,950 46,404,324 6.74%
PBT 12,991,243 12,940,670 10,627,282 10,501,010 9,965,362 10,837,124 10,770,776 3.17%
Tax -2,859,936 -3,833,565 -2,770,746 -2,389,534 -2,284,083 -2,512,708 -2,548,815 1.93%
NP 10,131,307 9,107,105 7,856,536 8,111,476 7,681,279 8,324,416 8,221,961 3.53%
-
NP to SH 9,763,934 8,936,769 7,643,713 7,844,493 7,439,321 8,033,346 7,989,354 3.39%
-
Tax Rate 22.01% 29.62% 26.07% 22.76% 22.92% 23.19% 23.66% -
Total Cost 58,533,222 49,741,376 37,655,020 41,444,060 44,147,003 42,001,534 38,182,363 7.37%
-
Net Worth 95,138,265 90,255,278 84,698,618 82,869,597 82,083,299 78,532,974 71,853,940 4.78%
Dividend
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Div 7,238,089 7,111,934 6,914,085 9,067,498 4,384,131 6,314,292 6,153,686 2.73%
Div Payout % 74.13% 79.58% 90.45% 115.59% 58.93% 78.60% 77.02% -
Equity
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Net Worth 95,138,265 90,255,278 84,698,618 82,869,597 82,083,299 78,532,974 71,853,940 4.78%
NOSH 12,066,952 12,054,127 11,970,013 11,693,337 11,241,361 11,241,361 10,945,196 1.63%
Ratio Analysis
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
NP Margin 14.75% 15.48% 17.26% 16.37% 14.82% 16.54% 17.72% -
ROE 10.26% 9.90% 9.02% 9.47% 9.06% 10.23% 11.12% -
Per Share
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
RPS 569.03 488.20 380.21 430.65 461.05 452.83 424.94 4.98%
EPS 80.91 74.14 63.86 68.17 66.18 72.28 73.16 1.69%
DPS 60.00 59.00 57.76 78.80 39.00 57.00 56.35 1.05%
NAPS 7.8842 7.4875 7.0759 7.2016 7.3019 7.0664 6.5799 3.05%
Adjusted Per Share Value based on latest NOSH - 11,970,013
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
RPS 569.03 487.68 377.16 410.67 429.51 417.06 384.56 6.74%
EPS 80.91 74.06 63.34 65.01 61.65 66.57 66.21 3.39%
DPS 60.00 58.94 57.30 75.14 36.33 52.33 51.00 2.74%
NAPS 7.8842 7.4795 7.0191 6.8675 6.8023 6.5081 5.9546 4.78%
Price Multiplier on Financial Quarter End Date
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Date 28/06/24 30/06/23 30/06/22 30/06/21 30/06/20 28/06/19 29/06/18 -
Price 9.96 8.63 8.59 8.11 7.51 8.88 9.00 -
P/RPS 1.75 1.77 2.26 1.88 1.63 1.96 2.12 -3.14%
P/EPS 12.31 11.64 13.45 11.90 11.35 12.28 12.30 0.01%
EY 8.12 8.59 7.43 8.41 8.81 8.14 8.13 -0.02%
DY 6.02 6.84 6.72 9.72 5.19 6.42 6.26 -0.64%
P/NAPS 1.26 1.15 1.21 1.13 1.03 1.26 1.37 -1.38%
Price Multiplier on Announcement Date
30/06/24 30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 CAGR
Date 28/08/24 30/08/23 25/08/22 26/08/21 27/08/20 29/08/19 30/08/18 -
Price 10.90 9.11 8.84 8.45 7.46 8.57 9.96 -
P/RPS 1.92 1.87 2.33 1.96 1.62 1.89 2.34 -3.24%
P/EPS 13.47 12.29 13.84 12.40 11.27 11.86 13.61 -0.17%
EY 7.42 8.14 7.22 8.07 8.87 8.43 7.35 0.15%
DY 5.50 6.48 6.53 9.33 5.23 6.65 5.66 -0.47%
P/NAPS 1.38 1.22 1.25 1.17 1.02 1.21 1.51 -1.48%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment